Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Lumos Diagnostics secures a six-year exclusive distribution agreement worth up to US$317 million with PHASE Scientific for FebriDx®.
Jul 16, 2025•11 months ago
Contract Type
agreement
BiotechnologyHealth CareMedicalMedical DeviceHealth Diagnostics
Description
Lumos Diagnostics has entered into a significant exclusive distribution agreement with PHASE Scientific, which could be worth up to US$317 million, pending FDA approval. The deal lays the groundwork for the rapid adoption of the FebriDx® test across the US healthcare system, enhancing its distribution capabilities significantly.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months